These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 11926724)

  • 1. Treatment of borderline personality disorder with risperidone.
    Rocca P; Marchiaro L; Cocuzza E; Bogetto F
    J Clin Psychiatry; 2002 Mar; 63(3):241-4. PubMed ID: 11926724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.
    Turgay A; Binder C; Snyder R; Fisman S
    Pediatrics; 2002 Sep; 110(3):e34. PubMed ID: 12205284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study.
    Bellino S; Paradiso E; Bogetto F
    J Clin Psychiatry; 2006 Jul; 67(7):1042-6. PubMed ID: 16889446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder.
    Benedetti F; Sforzini L; Colombo C; Maffei C; Smeraldi E
    J Clin Psychiatry; 1998 Mar; 59(3):103-7. PubMed ID: 9541151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target.
    Villeneuve E; Lemelin S
    J Clin Psychiatry; 2005 Oct; 66(10):1298-303. PubMed ID: 16259544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial.
    Bozzatello P; Rocca P; Uscinska M; Bellino S
    CNS Drugs; 2017 Sep; 31(9):809-819. PubMed ID: 28741044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-acting injectable risperidone in treatment resistant borderline personality disorder. A small series report].
    Díaz-Marsá M; Galian M; Montes A; Fernández R; Arza R; López-Ibor J; Carrasco J
    Actas Esp Psiquiatr; 2008; 36(2):70-4. PubMed ID: 18365787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label trial of divalproex extended-release in the treatment of borderline personality disorder.
    Simeon D; Baker B; Chaplin W; Braun A; Hollander E
    CNS Spectr; 2007 Jun; 12(6):439-43. PubMed ID: 17545954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quetiapine for the treatment of borderline personality disorder; an open-label study.
    Perrella C; Carrus D; Costa E; Schifano F
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):158-63. PubMed ID: 17045720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder.
    Bellino S; Paradiso E; Bogetto F
    Psychiatry Res; 2008 Nov; 161(2):206-12. PubMed ID: 18848360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD).
    Vieta E; Herraiz M; Fernández A; Gastó C; Benabarre A; Colom F; Martínez-Arán A; Reinares M
    J Clin Psychiatry; 2001 Aug; 62(8):623-30. PubMed ID: 11561935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder.
    Hollander E; Swann AC; Coccaro EF; Jiang P; Smith TB
    Am J Psychiatry; 2005 Mar; 162(3):621-4. PubMed ID: 15741486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder.
    Pinto OC; Akiskal HS
    J Affect Disord; 1998 Dec; 51(3):333-43. PubMed ID: 10333987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder.
    Van den Eynde F; Senturk V; Naudts K; Vogels C; Bernagie K; Thas O; van Heeringen C; Audenaert K
    J Clin Psychopharmacol; 2008 Apr; 28(2):147-55. PubMed ID: 18344724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities.
    Buitelaar JK; van der Gaag RJ; Cohen-Kettenis P; Melman CT
    J Clin Psychiatry; 2001 Apr; 62(4):239-48. PubMed ID: 11379837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine versus placebo in the treatment of borderline personality disorder.
    Bogenschutz MP; George Nurnberg H
    J Clin Psychiatry; 2004 Jan; 65(1):104-9. PubMed ID: 14744178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging evidence for the use of atypical antipsychotics in borderline personality disorder.
    Grootens KP; Verkes RJ
    Pharmacopsychiatry; 2005 Jan; 38(1):20-3. PubMed ID: 15706462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.
    Zanarini MC; Frankenburg FR; Parachini EA
    J Clin Psychiatry; 2004 Jul; 65(7):903-7. PubMed ID: 15291677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months.
    Research Units on Pediatric Psychopharmacology Autism Network
    Am J Psychiatry; 2005 Jul; 162(7):1361-9. PubMed ID: 15994720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.